These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 18042703)

  • 1. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.
    Zang X; Thompson RH; Al-Ahmadie HA; Serio AM; Reuter VE; Eastham JA; Scardino PT; Sharma P; Allison JP
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19458-63. PubMed ID: 18042703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.
    Zang X; Sullivan PS; Soslow RA; Waitz R; Reuter VE; Wilton A; Thaler HT; Arul M; Slovin SF; Wei J; Spriggs DR; Dupont J; Allison JP
    Mod Pathol; 2010 Aug; 23(8):1104-12. PubMed ID: 20495537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of B7-CD28 costimulation in urologic malignancies.
    Thompson RH; Kwon ED; Allison JP
    Immunotherapy; 2009 Jan; 1(1):129-39. PubMed ID: 20445772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases.
    Chavin G; Sheinin Y; Crispen PL; Boorjian SA; Roth TJ; Rangel L; Blute ML; Sebo TJ; Tindall DJ; Kwon ED; Karnes RJ
    Clin Cancer Res; 2009 Mar; 15(6):2174-80. PubMed ID: 19276267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
    Roth TJ; Sheinin Y; Lohse CM; Kuntz SM; Frigola X; Inman BA; Krambeck AE; McKenney ME; Karnes RJ; Blute ML; Cheville JC; Sebo TJ; Kwon ED
    Cancer Res; 2007 Aug; 67(16):7893-900. PubMed ID: 17686830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High B7-H3 expression is linked to increased risk of prostate cancer progression.
    Bonk S; Tasdelen P; Kluth M; Hube-Magg C; Makrypidi-Fraune G; Möller K; Höflmayer D; Dwertmann Rico S; Büscheck F; Minner S; Heinzer H; Graefen M; Hinsch A; Luebke AM; Dum D; Uhlig R; Schlomm T; Sauter G; Simon R; Weidemann SA
    Pathol Int; 2020 Oct; 70(10):733-742. PubMed ID: 32776718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis.
    Katayama A; Takahara M; Kishibe K; Nagato T; Kunibe I; Katada A; Hayashi T; Harabuchi Y
    Int J Oncol; 2011 May; 38(5):1219-26. PubMed ID: 21344157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer.
    Loos M; Hedderich DM; Ottenhausen M; Giese NA; Laschinger M; Esposito I; Kleeff J; Friess H
    BMC Cancer; 2009 Dec; 9():463. PubMed ID: 20035626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.
    Benzon B; Zhao SG; Haffner MC; Takhar M; Erho N; Yousefi K; Hurley P; Bishop JL; Tosoian J; Ghabili K; Alshalalfa M; Glavaris S; Simons BW; Tran P; Davicioni E; Karnes RJ; Boudadi K; Antonarakis ES; Schaeffer EM; Drake CG; Feng F; Ross AE
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):28-35. PubMed ID: 27801901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
    Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
    Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
    Kim GE; Kim NI; Park MH; Lee JS
    Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.
    Boorjian SA; Sheinin Y; Crispen PL; Farmer SA; Lohse CM; Kuntz SM; Leibovich BC; Kwon ED; Frank I
    Clin Cancer Res; 2008 Aug; 14(15):4800-8. PubMed ID: 18676751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction.
    Leitner J; Klauser C; Pickl WF; Stöckl J; Majdic O; Bardet AF; Kreil DP; Dong C; Yamazaki T; Zlabinger G; Pfistershammer K; Steinberger P
    Eur J Immunol; 2009 Jul; 39(7):1754-64. PubMed ID: 19544488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
    Liu Y; Vlatkovic L; Sæter T; Servoll E; Waaler G; Nesland JM; Giercksky KE; Axcrona K
    Int J Urol; 2012 Aug; 19(8):749-56. PubMed ID: 22487487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of T cells with fibroblast-like synoviocytes: role of the B7 family costimulatory ligand B7-H3.
    Tran CN; Thacker SG; Louie DM; Oliver J; White PT; Endres JL; Urquhart AG; Chung KC; Fox DA
    J Immunol; 2008 Mar; 180(5):2989-98. PubMed ID: 18292521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors.
    Yuan Z; Gardiner JC; Maggi EC; Huang S; Adem A; Bagdasarov S; Li G; Lee S; Slegowski D; Exarchakis A; Howe JR; Lattime EC; Zang X; Libutti SK
    Endocr Relat Cancer; 2021 Feb; 28(2):135-149. PubMed ID: 33410766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fine tuning the immune response through B7-H3 and B7-H4.
    Yi KH; Chen L
    Immunol Rev; 2009 May; 229(1):145-51. PubMed ID: 19426220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
    Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H3 over expression in prostate cancer promotes tumor cell progression.
    Yuan H; Wei X; Zhang G; Li C; Zhang X; Hou J
    J Urol; 2011 Sep; 186(3):1093-9. PubMed ID: 21784485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma.
    Sun J; Chen LJ; Zhang GB; Jiang JT; Zhu M; Tan Y; Wang HT; Lu BF; Zhang XG
    Cancer Immunol Immunother; 2010 Aug; 59(8):1163-71. PubMed ID: 20333377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.